Search hospitals > Pennsylvania > Philadelphia

Temple University Hospital

Claim this profile
Philadelphia, Pennsylvania 19140
Global Leader in Parotid Gland Cancer
Global Leader in Fibrosing Colonopathy
Conducts research for Lung Cancer
Conducts research for Coronavirus
Conducts research for Fibrosing Alveolitis
392 reported clinical trials
58 medical researchers
Photo of Temple University Hospital in PhiladelphiaPhoto of Temple University Hospital in PhiladelphiaPhoto of Temple University Hospital in Philadelphia

Summary

Temple University Hospital is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Parotid Gland Cancer, Fibrosing Colonopathy, Lung Cancer, Coronavirus, Fibrosing Alveolitis and other specialties. Temple University Hospital is involved with conducting 392 clinical trials across 888 conditions. There are 58 research doctors associated with this hospital, such as Gerard J Criner, Deric C. Savior, Hossein Borghaei, and Angela Jain, MD.

Area of expertise

1Parotid Gland Cancer
Global Leader
Temple University Hospital has run 52 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Fibrosing Colonopathy
Global Leader
Temple University Hospital has run 40 trials for Fibrosing Colonopathy. Some of their research focus areas include:
6MWD
CTD-ILD
rs3570920 TT positive

Top PIs

Clinical Trials running at Temple University Hospital

Breast Cancer
Lung Cancer
Parotid Gland Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Idiopathic Pulmonary Fibrosis
Prostate Cancer
Oropharyngeal Carcinoma
Stroke
Chronic Obstructive Pulmonary Disease
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Questionnaire Choice

for Cancer Data Quality

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Temple University Hospital?
Where is Temple University Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Temple University Hospital accept?
What awards or recognition has Temple University Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security